Loading clinical trials...
Loading clinical trials...
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of California, San Francisco
Collaborators
NCT04855435 · Advanced Solid Tumor, Uveal Melanoma, Metastatic, and more
NCT05588453 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, and more
NCT07627698 · Unresectable Melanoma, Metastatic Cutaneous Melanoma, and more
NCT05039801 · Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, and more
NCT06391099 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, and more
University of California, San Francisco
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions